Not recruiting
Hepatic function abnormal
Not recruitingEffect of moderate or severe liver impairment on the pharmacokinetics, safety and tolerability of camizestrant in post‑menopausal women
InvestigationalNo placebo
Effect of moderate or severe liver impairment on the pharmacokinetics, safety and tolerability of camizestrant in post‑menopausal women
InvestigationalNo placebo
- Disease:Hepatic function abnormal
- Substances:Camizestrant
Countries:
Bulgaria
Bulgaria- Participants:18–64 years · 65+ years · Healthy volunteers
- Substances:Camizestrant
- Sponsor:AstraZeneca AB


